Completed NA INTERVENTIONAL 1-arm NCT01610427

Study to Optimize the Quality of Samples for Cell-mediated Immunity (CMI) in ART-naïve HIV-1-infected Subjects

Optimizing the Quality of Samples Used for the Evaluation of Cell-mediated Immune (CMI) Responses in Antiretroviral Therapy (ART)-naïve Human Deficiency Virus Type 1 (HIV-1)-Infected Subjects

Sponsor: GlaxoSmithKline

Conditions AIDS AIDS Vaccines

Interventions Blood sample collection

Updated 9 times since 2017 Last updated: Apr 14, 2020 Started: Jun 25, 2012 Primary completion: Oct 30, 2012 Completion: Oct 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates AIDS and AIDS Vaccines and is currently completed. GlaxoSmithKline leads this study, which shows 9 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed NA
Sep 2024 — Sep 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2023 — Jul 2024 [monthly]

Completed NA
Dec 2022 — Jan 2023 [monthly]

Completed NA

▶ Show 4 earlier versions

Jan 2021 — Dec 2022 [monthly]

Completed NA
May 2020 — Jan 2021 [monthly]

Completed NA
Jun 2018 — May 2020 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Jun 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ghent, Belgium